Monday 5/19 Insider Buying Report: HUM, CVRX
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2025
0mins
Source: NASDAQ.COM
Humana Insider Purchase: Humana's CEO, James A. Rechtin, bought 6,530 shares of HUM for $1.5M at $229.25 each, seeing an 8% gain during the trading session as HUM rose to $247.62.
CVRx Insider Purchase: Kirk G. Nielsen purchased 187,813 shares of CVRx for $977,346 at $5.20 each, with a notable 32% gain at the peak of the trading session as CVRx reached $6.87.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like HUM with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on HUM
Wall Street analysts forecast HUM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUM is 290.39 USD with a low forecast of 231.00 USD and a high forecast of 344.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
6 Buy
12 Hold
1 Sell
Moderate Buy
Current: 194.010
Low
231.00
Averages
290.39
High
344.00
Current: 194.010
Low
231.00
Averages
290.39
High
344.00
About HUM
Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UnitedHealth Group 2025 Earnings Report Analysis
- Earnings Beat Expectations: UnitedHealth Group's Q4 2025 earnings report exceeded expectations; however, the stock plummeted 20%, indicating market disappointment with future revenue guidance, resulting in a more than 50% decline from its late 2024 peak.
- Impact of Insurance Policy: The Centers for Medicare & Medicaid Services (CMS) proposed a mere 0.09% increase in 2027 Medicare Advantage rates, significantly below the anticipated 4% to 6%, placing substantial financial pressure on UnitedHealth Group, which leads the Medicare market.
- CEO's Outlook: CEO Timothy Noel emphasized during the earnings call that the CMS proposal does not reflect the realities of medical utilization and cost trends, potentially leading to significant benefit reductions and necessitating a reevaluation of the company's geographic and product footprint.
- Long-Term Growth Potential: Despite short-term challenges, UnitedHealth Group anticipates modest growth in 2026 and a return to low double-digit earnings growth in 2027, with CEO Stephen Hemsley asserting that the company can achieve long-term growth rates of 13% to 16%, presenting potential long-term investment opportunities for shareholders.
Continue Reading
Trump Administration's Medicare Proposal Shocks Healthcare Stocks
- Payment Increase Proposal: The Centers for Medicare and Medicaid Services proposed a mere 0.09% net increase in Medicare Advantage payments for 2027, significantly below the anticipated 4% to 6%, resulting in a $90 billion market value loss for the healthcare sector, highlighting the substantial impact of policy uncertainty on market dynamics.
- Earnings Risk Heightened: Analysts warn that if the proposed rates are finalized without adjustments, insurers could see a 15% to 20% decrease in earnings due to the disconnect between rising medical costs and flat funding, exacerbating profitability pressures within the industry.
- Bleak Industry Outlook: Although final rates are expected in April and historical trends suggest potential improvements, analysts predict the healthcare sector may enter a stagnation period of one to two years where earnings fail to expand as previously hoped, negatively affecting investor sentiment.
- Operational Improvements Overlooked: Despite UnitedHealth reporting quarterly improvements in profitability, the headline risk from the payment proposal continues to overshadow operational gains, with analysts noting that while progress is being made, significant recovery challenges remain.
Continue Reading